Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma

Cytomegalovirus reactivation with bendamustine in patients with low-grade B-cell lymphoma

(2014) Tetsuo Hasegawa et al.   ANNALS OF HEMATOLOGY

Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab

(2014) Ricardo García Muñoz et al.   ANNALS OF HEMATOLOGY

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

(2014) I. W. Flinn et al.   BLOOD

Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer

(2013) Rachel M. Layman et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2013) Ken Ohmachi et al.   JOURNAL OF CLINICAL ONCOLOGY

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

(2013) Mathias J Rummel et al.   LANCET

Bendamustine can severely impair T-cell immunity against cytomegalovirus

(2012) Toru Hosoda et al.   LEUKEMIA & LYMPHOMA

Reactivation of hepatitis B virus following bendamustine-containing chemotherapy in a patient with multiple myeloma

(2011) Umit Tapan et al.   LEUKEMIA & LYMPHOMA

Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma

(2010) Ken Ohmachi et al.   CANCER SCIENCE

Pneumocystis jirovecipneumonia in relation to CD4+ lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy

(2010) Kenji Hashimoto et al.   LEUKEMIA & LYMPHOMA